CLARITY - Key Persons
Job Titles:
- Non - Executive Director
- SCIENTIFIC ADVISOR
- Senior Leader
Ms Maley is an experienced senior leader with over 25 years of experience in the pharmaceutical industry. Her most recent role was the General Manger, Novartis Oncology, Australia and New Zealand. She has a strong strategic, commercial background with a proven track record in product launch excellence and timely patient access to innovative medicines. She has worked in the US, Philippines and Australia with local, regional and global responsibilities.
Ms Maley has a Bachelor of Science Degree, a Diploma of Education, a Master of Business Administration and is a Graduate of the Australian Institute of Company Directors. She has a passion for innovation and has completed formal innovation training both in Australia and USA. She is also a graduate of an Executive Female Leadership Program from Novartis (Switzerland). Ms Maley currently serves as a Non-Executive Director for ASX listed biotech company Medlab Clinical.
David joined the Company in January 2022 and is now serving as Clarity's Chief Financial Officer responsible for the overall financial management of the Company including IT and HR.
David comes to the role with over 25 years' experience in performing senior finance roles for listed and unlisted companies, including Pacific Dunlop Limited, Sigma Pharmaceuticals, Alchemia Limited, Chiquita Brands South Pacific Limited (now Costa Group) and Ellume Limited. David commenced his career with Ernst & Young in Australia and Europe.
As a proven CFO, David has extensive experience in complex operating environments across multiple geographies, private treaty and public company transactions, treasury operations and debt and equity markets.
David is a Chartered Accountant and holds a Bachelor of Economics (Monash University) and Masters of Applied Finance (Securities Institute of Australia).
Job Titles:
- Executive Chairman
- SCIENTIFIC ADVISOR
Dr Taylor joined the Board in November 2013 as Executive Chairperson.
Dr Taylor has been instrumental in the growth of the Company and has been heavily involved in all areas of the Company's business. Dr Taylor has approximately 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Dr Taylor was an Executive Director of Inteq Limited, a boutique Australian investment bank.
After receiving the University Medal for his undergraduate degree in Applied Science at the University of Sydney, Dr Taylor completed his PhD in Medicine at the Garvan Institute of Medical Research. Dr Taylor has also completed a Graduate Diploma in Applied Finance at the Securities Institute of Australia.
Job Titles:
- Non - Executive Director
- SCIENTIFIC ADVISOR
Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. Dr Roberts was previously the CEO of ASX-listed company Cochlear Limited and Chairman of ASX-listed company Sirtex Medical Ltd. Dr Roberts was also Executive Vice-President and a director of the dual-listed (ASX and NYSE) company ResMed Inc., a global sleep disorder treatment company.
Dr Roberts holds a Bachelor of Engineering (Honours) in Chemical Engineering from the University of New South Wales, an MBA from Macquarie University and a PhD from the University of New South Wales. He has also been awarded Honorary Doctor of Science degrees from Macquarie University and the University of New South Wales.
Job Titles:
- CEO
- Managing Director
- SCIENTIFIC ADVISOR
Dr Biggin joined the Board in October 2019 as Managing Director and CEO after playing an instrumental role in enhancing and designing the Company's product development and clinical programmes since he first joined the Company in January 2017.
Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo® (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
Dr Biggin holds a Bachelor of Science (Honours) and a PhD from the University of Glasgow.
Matt was part of the founding group, TM Ventures, and the first Managing Director from 2010 until 2018. He is currently Director of Technology at Clarity.
Matt has approximately 20 years of combined experience in cancer research, nuclear medicine and business and has a PhD in cancer research from the Australian National University. Matt brings expertise in biotechnology, radiopharmaceuticals, academic research and investment to the Company and focuses on developing the technology behind the Company's products.
Matt has an MBA from the Australian Graduate School of Management. He has held leading managerial positions and director roles in several early stage Australian life science companies.
Job Titles:
- Non - Executive Director
- SCIENTIFIC ADVISOR
Dr Ramdahl is a pharmaceutical executive with over 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. When Dr Ramdahl joined Algeta, he was one of six employees and he played an instrumental role in its success, serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014 for US$2.9 billion. Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. Dr Ramdahl currently serves as Chairman of Precirix (Belgium), AppSens AS (Norway) and Nordic Nanovector (Norway).
Dr Ramdahl gained his PhD in Environmental Chemistry from the University of Oslo and holds a Master of Science in Organic Chemistry from the Norwegian Institute of Technology.
Job Titles:
- Director of the Idaho Accelerator Center
Mr Stoner is the director of the Idaho Accelerator Center (IAC), a research institute of Idaho State University. He has been researching isotope production using linear accelerators for 14 years and pioneered a new process and mechanism for producing therapeutic copper-67 that enables it to be manufactured in the quantities and quality required for clinical development. He has 10 years of experience in production of the copper-67 isotope, and under his leadership the IAC has been shipping copper-67 commercially since 2014, supporting Clarity's Targeted Copper Theranostic programs from preclinical through to the clinic where there are now three therapy products in clinical development.
Mr Stoner has 3 patents on production of copper-67 and has 11 related publications. He has worked in many technical and business roles in high technology for more than 34 years including Sr. VP and Chief Technology Officer of AMI Semiconductor where he was responsible for world-wide R&D and Intellectual Property, General Manager of the Image Sensor Business Unit and Founder and Managing Partner of C&J Tech Consulting - a company supplying technical evaluation support to Private Equity investors and other clients.
Job Titles:
- Vice President - Regulatory and Quality
She has twenty-plus years' experience in the biotech and pharmaceutical industry. Kat has held global and affiliate positions across numerous therapeutic areas (oncology, multiple sclerosis, rare disease), building and leading regulatory and quality teams dedicated to making a difference for better patient outcomes. Throughout her career, Kathryn has held significant positions in notable companies such as Merck, Sandoz, Sanofi and Genzyme.
Job Titles:
- SCIENTIFIC ADVISOR
- Executive Vice President - Global Clinical Operations
Michelle joined the Company in June 2018 and is the Company's Executive Vice President of Global Clinical Operations.
Michelle has over 20 years of experience spanning across nuclear medicine/PET and pharmaceutical industries both in Australia and internationally. Prior to joining the Company, Michelle held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, leading a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution.
Michelle holds a Bachelor of Applied Science in Medical Radiation Technology (Nuclear Medicine) from the University of Sydney.
Professor Kjaer is a professor at the University of Copenhagen and a chief physician at the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet, the National University Hospital of Denmark.
Professor Kjaer is a former president of the Scandinavian Society of Clinical Physiology and Nuclear Medicine (SSCPNM) and served on the Scientific Committee of the Danish Cancer Society and the European Association of Nuclear Medicine (EANM) Oncology Committee. He is currently a member of the scientific advisory board of the European Neuroendocrine Tumor Society (ENETS) and a member of the Industrial Research Committee of the Innovation Fund Denmark. Professor Kjaer is founding Editor-in-Chief of Diagnostics (Basel), head of the Cluster for Molecular Imaging, and director of the Postgraduate School for Medical and Molecular Imaging at the Faculty of Health Sciences, University of Copenhagen. He is an elected member of the Danish Academy of Technical Sciences and a Knight of the Order of Dannebrog, a Danish Royal Order of Chivalry.
Professor Kjaer has published more than 500 peer-reviewed articles and received numerous prestigious scientific awards over the years.
Dr Iagaru is a Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University. His research focus includes PET/MRI and PET/CT imaging for early cancer detection as well as peptide-based diagnostic imaging and therapy. Dr Iagaru is also passionate about clinical translation of novel PET radiopharmaceuticals.
Job Titles:
- Emily Tow Jackson Chair
- Professor
Professor Lewis is the Emily Tow Jackson Chair in Oncology and serves as Vice Chair for Research in the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK), Chief of MSK's Radiochemistry & Imaging Sciences Service, and Director of MSK's Radiochemistry and Molecular Imaging Probe Core Facility. He is head of a laboratory in the Sloan Kettering Institute's Molecular Pharmacology Program and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill Cornell Medical College. He is an Adjunct Professor in the Department of Biomedical Imaging and Image Guided Therapy, The Medical University of Vienna, Austria.
Professor Lewis holds a PhD from The University of Kent (UK) and has published over 300 papers, books, book chapters, and reviews in the field of cancer imaging. He has served as the President of the World Molecular Imaging Society and was named a Fellow (FWMIS) in 2015. He has received the SNMMI Michael J. Welch award, the Paul C. Aebersold Award for Outstanding Achievement in Basic Science Applied to Nuclear Medicine, the Distinguished Investigator Award from the Academy of Radiology Research and the ACS Bioconjugate Chemistry Lectureship Award. He has been named a Fellow of the Society of Nuclear Medicine and Molecular Imaging (FSNMMI), a Fellow of the Royal Society of Chemistry (FRSC) and a Fellow of the American Association for the Advancement of Science (FAAAS). In 2019 Professor Lewis was awarded an NCI Outstanding Investigator Award (R35) to support his work in radiochemistry and molecular imaging.
Job Titles:
- Director of Theranostics and Nuclear Medicine at St Vincent 's Hospital Sydney
Prof Emmett is the Director of Theranostics and Nuclear Medicine at St Vincent's Hospital Sydney, a conjoint professor of medicine at the University of New South Wales and clinical research leader at the Garvan Institute of Medical Research. Since joining the Nuclear Medicine and Positron Emission Tomography (PET) department at St Vincent's Hospital in 2012, Prof Emmett has been instrumental in developing the theranostics initiative at the St Vincent's Campus, introducing new radiopharmaceuticals for clinical and research evaluation of cancer as well as setting up radiopharmacy production of a number of imaging and therapy tracers.
Prof Emmett is heavily involved in multidisciplinary clinical development and cancer research, including both imaging and therapy. She is the principal investigator of a number of prospective randomised national trials in Australia, being a big believer in the power of clinical research to optimise treatments and improve patients' lives. She is passionate about translational science, collaborating with biotechnology companies to bring promising theranostic agents into the clinic.
Prof Emmett completed medical school at Auckland University (1992), New Zealand prior to completing her specialty training in Nuclear Medicine in Sydney and receiving her Fellow of the Royal Australasian College of Physicians (FRACP) qualification in 1999. She undertook a specialty fellowship in Nuclear Cardiology at the University Health Network in Toronto, Canada in 2001, and completed a Doctorate of Medicine in Nuclear Cardiology through Auckland University in 2014. Prof Emmett is a clinical professor with the University of New South Wales with a strong interest in research. She has published over 100 original papers in peer reviewed journals in the last 10 years, has received a number of grants for clinical research and has presented at numerous national and international meetings.
Professor Sartor is a medical oncologist and an internationally recognised expert in prostate cancer. He is the Laborde Professor for Cancer Research, Medical Director of the Tulane Cancer Center, and Assistant Dean for Oncology at Tulane University School of Medicine in New Orleans, Louisiana.
Professor Sartor is a past member of the Board of Scientific Counselors (Clinical Sciences and Epidemiology) at the National Cancer Institute and previously served as Chairman of the Prostate Cancer Integration Panel for the US Department of Defense. Professor Sartor has chaired five Data Monitoring Committees for Phase III trials that lead to FDA approval. He is medical oncology chair of the Genitourinary committee of NRG Oncology.
Professor Sartor received his Doctor of Medicine from Tulane University with honours in 1982. After his internship at the University of Pennsylvania, he trained in Internal Medicine at Tulane Medical School. After completing his fellowship at the National Cancer Institute in Bethesda, Maryland in 1989, he served until 1993 as a Senior Investigator at the National Cancer Institute with a focus on novel therapeutics for advanced prostate cancer patients.
Professor Donnelly is the Clarity Group leader of the Donnelly Research Group, The University of Melbourne, based in the state-of-art laboratories of the Bio21 Institute of Molecular Science and Biotechnology.
Professor Donnelly's expertise is in the application of synthetic inorganic/organic chemistry in biology and materials science, with a particular focus on the application of coordination chemistry to metal based drugs and the study of metal ions in biological systems. Professor Donnelly has an impressive publication record and is the inventor of a number of novel and patented radiopharmaceutical technologies.
Job Titles:
- Director
- Professor, Chairman
Professor Wahl is the Elizabeth Mallinckrodt Professor, Chairman of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St Louis.
Professor Wahl is recognised as a world leader in the field of targeted radiopharmaceuticals for diagnosing and treating cancer. With an emphasis on PET and multi-modality imaging, such as PET-CT, his work enables precision diagnosis of a broad array of human cancers and other serious diseases. Professor Wahl is one of the inventors of radio-immunotherapy of lymphoma, which is a combination of radiotherapy and immunotherapy that facilitates targeted treatments. He has also been an inventor of a number of FDA approved medical devices, such as radionuclide guided biopsy.
Professor Wahl holds 18 radiology patents and has published more than 450 peer-reviewed scientific papers and several books. He has served as a chairman of the American Board of Nuclear Medicine (ABNM), president of the Institute for Clinical PET (ICP) program, refresher course chair for Radiological Society of North America and on multiple NIH study sections. He was elected as a member of the US National Academy of Medicine in 2015. Most recently, Professor Wahl was elected 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Job Titles:
- Lead Independent Director
- Non - Executive Director
- SCIENTIFIC ADVISOR
Mr Thomas has a strong background in financial services and capital markets and has considerable expertise in mergers & acquisitions, including advising on the IPOs of the Commonwealth Bank of Australia and Qantas. Mr Thomas is the former CEO of County NatWest Securities and the former CEO (and then Chairman) of Citi Corporate and Investment Bank Australasia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's largest life insurance company) and the previously ASX-listed company HeartWare® International Inc. Mr Thomas is the Chairman of AusBio Ltd, Grahger Retail Securities Pty Ltd and ASX-listed Starpharma Holdings Limited, and is a non-executive director of Biotron Limited and O'Connell Street Associates. He is a past non-executive director of Reva Medical Inc. and Virgin Australia.
Mr Thomas holds a Bachelor of Economics from Monash University and a Diploma of Business (Accounting) from Swinburne. He is a Fellow of the Securities Institute of Australia, Fellow of the Australian Institute of Company Directors and a Fellow of the Royal Society of New South Wales. He is also Co-Chair of the State Library of New South Wales Foundation.
Robert joined the Company in July 2019 as Clarity's Chief Financial Officer and is now serving as Company Secretary.
Robert is a finance and governance executive with over 30 years of experience and has had extensive involvement in life sciences and early stage businesses. Prior to joining the Company, Robert led the finance function at the previously ASX-listed company, Viralytics Limited, and was a key member of the due diligence target team during the trade sale negotiations and due diligence process with the purchaser of the company (Merck & Co), liaising with legal and investment banking teams, as well as leading the finance, IT and HR integration efforts post acquisition.
Robert holds a Bachelor of Commerce from the University of New South Wales and is an Associate
Job Titles:
- Non - Executive Director
- SCIENTIFIC ADVISOR
Ms Robinson brings extensive experience in the nuclear field and a range of commercial expertise to the Company and has over 25 years of experience in both governance and management roles in public and private companies and government. Ms Robinson is the General Manager of Business Development at Australian Nuclear Science and Technology Organisation. Ms Robinson's in-depth knowledge of the nuclear medicine industry provides the Company with a clear vision across the dynamics of, and most recent changes in, the sector.
Ms Robinson holds a Bachelor of Business (Accounting), a Graduate Diploma of Accounting (CA) and is a Graduate of the Australian Institute of Company Directors.
Shaemus Gleason Executive Vice President - Operations Shaemus joined the Company in May 2021 and is the Company's Executive Vice President of Operations. Shaemus has over 13 years of experience spanning across all facets of targeted radionuclide therapies and diagnostic radiopharmaceuticals. Prior to joining the Company, Shaemus was a member of the oncology strategy business unit at Bayer/Algeta where he was responsible for the technical operations in their phase I targeted alpha therapy development globally. Prior to this, he held a leadership role on the US commercial organisation supporting a marketed product Xofigo® (radium-223 dichloride) for metastatic prostate cancer.